Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term BMD Study of Relugolix Combination Tablet in Uterine Fibroids and Endometriosis
NCT05862272Phase 3Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2023
- Primary completion
- Jul 2029
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of relugolix in Uterine Fibroids (UF), endometriosis, sponsored by Sumitomo Pharma. Started Aug 2023; status: recruiting.
02
Drugs
relugolix
03
Conditions
Uterine Fibroids (UF)endometriosis
Beyond the preview
Go deeper on NCT05862272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862272.